TGTX - Latest News
TG Therapeutics, Inc. (TGTX), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $6.53B. Trailing twelve-month P/E ratio is 13.34. Beta to the broader market is 1.68.
The article list below shows the most recent TGTX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent TGTX Headlines
Historic Signal Says This Biotech Outperforms
schaeffersresearch.com - May 11, 2026
TG Therapeutics Inc (NASDAQ:TGTX) is trading down 1. 2% at $42.
TGTX Q1 Earnings Miss, Sales Rise Y/Y, Stock Up on Raised 2026 View
zacks.com - May 7, 2026
TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.
TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript
seekingalpha.com - May 6, 2026
TG Therapeutics, Inc.
TG Therapeutics (TGTX) Q1 Earnings Lag Estimates
zacks.com - May 6, 2026
TG Therapeutics (TGTX) came out with quarterly earnings of $0. 17 per share, missing the Zacks Consensus Estimate of $0.
TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance
globenewswire.com - May 6, 2026
First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U. S.
How News Affects TGTX Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track TGTX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked TGTX news questions
- What is the latest TGTX news headline?
- The most recent TGTX headline (May 11, 2026) is "Historic Signal Says This Biotech Outperforms". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the TGTX news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What TGTX news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual TGTX options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.